サポート ブログ AI Deep Learning Models in Antibody Research

AI Deep Learning Models in Antibody Research

Biointron 2024-01-24 Read time: 4 mins
AI LSTM
Antibody design using LSTM-based deep generative model from phage display library for affinity maturation. Image credit: DOI: 10.1038/s41598-021-85274-7

Although the incorporation of artificial intelligence (AI) in antibody research is still in its early stages, research scientists studying AI, bioinformatics, and protein engineering have used AI models to demonstrate its potential to transform the R&D space of the biotech and pharmaceutical industries.

The accessibility of high-throughput experimental data has also enabled a shift in antibody research from being experiment-focused to data-centric. AI models like CNN and LSTM have been used to investigate the sequence, structure, and functionality of antibodies, as well as AI-fueled protein structure modeling platforms like AlphaFold2.1

CNN 

A convolutional neural network (CNN) is a deep learning model that is useful for analyzing visual imagery. It utilizes convolutional layers (sliding filters) across the input domain, transforming the input to degrees of filter matching for each filter. A protein structure can be rendered into a compatible format for the convolutional filters, such as a graph, manifold or 3D voxel grid.2

LSTM 

A long short-term memory (LSTM) network is another deep learning model that is designed to process and make predictions based on sequences of data. It uses memory cells and gates to capture important information and predict what comes next in the sequence, even when there are long-term dependencies or patterns.3

Mason et al. (2021) used CNNs and LSTMs for antibody lead optimization, successfully predicting antigen specificity from a diverse space of antibody sequences. By deep-sequencing libraries of the existing therapeutic antibody trastuzumab, they generated approximately 1 × 104 variants via site-directed mutagenesis to screen for specificity to human epidermal growth factor receptor 2 (HER2). The sequences were used as input to CNNs and LSTMS which were trained to predict the binding label of the sequences. They used these neural networks to filter a computationally generated set of candidate sequences to HER2-specific predicted binders. By testing for viscosity, clearance, solubility and immunogenicity, the researchers generated thousands of highly optimized lead candidates. Experimental testing revealed 30 out of 30 randomly selected predicted variants retained specificity to the target antigen HER2.4

Therefore, sequence-based methods may be advantageous over traditional structure-based methods, which are more time-consuming and resource-demanding due to the low-throughput screening of full-length antibodies. Meanwhile, sequence-based methods have more data available from developed experimental methods such as next-generation sequencing.

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References:

  1. Antibody Therapeutics. (2022, February 23). Call for Papers: Artificial Intelligence in antibody discovery, development and beyond. https://academic.oup.com/abt/pages/call-for-papers-artificial-intelligence-in-antibody-discovery-development-and-beyond

  2. Graves, J., Byerly, J., Priego, E., Makkapati, N., Parish, S. V., Medellin, B., & Berrondo, M. (2020). A Review of Deep Learning Methods for Antibodies. Antibodies, 9(2). https://doi.org/10.3390/antib9020012

  3. Sepp Hochreiter, Jürgen Schmidhuber; Long Short-Term Memory. Neural Comput 1997; 9 (8): 1735–1780. doi: https://doi.org/10.1162/neco.1997.9.8.1735

  4. Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., Correia, B. E., & Reddy, S. T. (2021). Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nature Biomedical Engineering, 5(6), 600-612. https://doi.org/10.1038/s41551-021-00699-9


Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。